User menu

Predictors of Acamprosate Efficacy: Results from a Pooled Analysis of Seven European Trials including 1485 alcohol-dependent patients

Bibliographic reference Verheul, Roel ; van den Brink, Wim ; Koeter, Maarten W. J. ; Geerlings, Peter J. ; Lehert, Philippe. Predictors of Acamprosate Efficacy: Results from a Pooled Analysis of Seven European Trials including 1485 alcohol-dependent patients. In: Psychopharmacology, Vol. 178, no. 2-3, p. 167-173 (2005)
Permanent URL
  1. Ait-Daoud N, Johnson BA, Prihoda TJ et al. (2001) Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence. Psychopharmacology 154:23?27
  2. Anderson TW (1957) Maximum likelihood estimates for a multivariate normal distribution when some observations are missing. J Am Statist Assoc 52:200?203
  3. Besson J, Aeby F, Kasas A et al. (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res 22:573?579
  5. Choi CC (1998) Sample size in clinical trials with dichotomous endpoints, use of covariables. J Biopharm Stat 8:367?375
  6. Cloninger CR (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236:410?416
  7. Fleiss J (1985) Design and analysis of clinical experiments. Wiley, New York, pp 100?101
  8. Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Eur Addict Res 3:129?137
  9. Gerra G, Caccavari R, Delsignore R et al. (1992) Effects of fluoxetine and Ca-acetyl-homotaurinate on alcohol intake in familial and nonfamilial alcoholic patients. Curr Ther Res 52:291?295
  10. Gerra G, Ferri M, Zaimovic A et al. (1998) GABAergic function in detoxified heroin addicts: relationship to anxiety disorders. Psychiatry Res 77:89?96
  11. Gual A, Lehert Ph (2001) Acamprosate during and after acute alcohol withdrawal: a double blind placebo controlled study in Spain. Alcohol Alcohol 36:413?418
  12. Johnson BA, Roache JD, Javors MA et al. (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 284:963?971
  13. Kiefer F, Jahn H, Tarnaske T et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92?99
  14. Koele P (1982) Calculating power in analysis of variance. Psychol Bull 92:513?516
  15. Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25:1335?1341
  16. Ladewig D, Knecht T, Lehert P et al. (1993) Acamprosate: a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50:182?188
  17. Lehert Ph (1994) Guidelines on evaluation of treatment of alcohol dependence. Alcoholism 59:67
  18. LESCH O. M., WALTER H., SUBTYPES OF ALCOHOLISM AND THEIR ROLE IN THERAPY, 10.1093/oxfordjournals.alcalc.a008221
  19. Little RJA, Rubin DB (1987) Statistical analysis with missing data. Wiley, New York
  20. Littleton J (1995) Acamprosate in alcohol dependence: how does it work? Addiction 90:1179?1188
  21. Littleton J., al Qatari M., Little H., The Neurobiology of Craving: Potential Mechanisms for Acamprosate, Acamprosate in Relapse Prevention of Alcoholism (1996) ISBN:9783642801952 p.27-46, 10.1007/978-3-642-80193-8_2
  22. Mason BJ (2001) Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 62(Suppl 20):42?48
  23. Monterosso JR, Flannery BA, Pettinati H et al. (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10:258?268
  24. Oslin DW, Berrettini W, Kranzler HR et al. (2003) A functional polymorphism of the ?-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546?1552
  25. Pelc I, Verbanck P, Le Bon O et al. (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry 171:73?77
  26. Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92:1537?1546
  27. Samson HH, Harris RA (1992) The neurobiology of alcohol abuse. Trends Pharmacol Sci 13:206?211
  28. Sass H (1995) Results from a pooled analysis of 11 European trials comparing acamprosate and placebo in the treatment of alcohol dependence [abstract]. Alcohol Alcohol 30:551
  29. Sass Henning, Relapse Prevention by Acamprosate : Results From a Placebo-Controlled Study on Alcohol Dependence, 10.1001/archpsyc.1996.01830080023006
  30. Schuckit MA (1996) Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psychol 64:669?676
  31. Spanagel R, Zieglgänsberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18:54?59
  32. Tempesta E, Janiri L, Bignamini A et al. (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence. A placebo-controlled study. Alcohol Alcohol 35:202?209
  33. Tsai GE, Ragan P, Chang R et al. (1998) Increased glutamatergic neurotransmission and oxidative stress after alcohol withdrawal. Am J Psychiatry 155:726?732
  34. Van den Brink W (2003) The role of psychosocial interventions in the pharmacological treatment of alcohol dependence. Drugs Ther Perspect 2:16?21
  35. Verheul R, van den Brink W, Geerlings PJ (1999) A three-pathway psychobiological model of craving for alcohol. Alcohol Alcohol 34:197?222
  36. Whitworth AB, Fischer F, Lesch OM et al. (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 347:1438?1442
  37. Wilde MI, Wagstaff AJ (1997) Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs 53:1038?1053
  38. Winer BJ (1989) Statistical principles in experimental design, 3rd edn. McGraw Hill, New York